← Who reports today · Health Care
How Pfizer (PFE) makes money: Q3 2026 revenue breakdown
Net income attributable to Pfizer Inc. common shareholders
$3,242M
down 8.4% y/y
Total revenues
$16,583M
down 0.4% y/y
Next report
~ Feb 2
not announced yet
The quarter in brief
Pfizer's third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier (-0.4%), while GAAP net income fell 8% to $3,242 million and diluted EPS declined to $0.56 from $0.62. Pre-tax income from continuing operations edged up to $3,385 million from $3,334 million, but a tax charge of $134 million replaced a $216 million benefit.
Key growth driver: Alliance revenues — the fastest-growing revenue line: $2,851, +24% y/y. · by the Q3 2026 report
How does Pfizer make money?
Pfizer brought in $16.6 billion of revenue in Q3 2026, down 0.4% year over year. The largest source was Product revenues: $13.3 billion, or 80% of the total, followed by Alliance revenues ($2.85B, 17%) and Royalty revenues ($477M, 3%). Net income for the quarter was $3.24 billion, down 8.4% year over year.
Revenue by source, Q3 2026
- Product revenues$13.3B · 80% · −4.8%
- Alliance revenues$2.85B · 17% · +24.1%
- Royalty revenues$477M · 3% · +9.4%
Shares of $16.6B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Product revenues | $13,255 · −4.8% |
| Alliance revenues | $2,851 · +24.1% |
| Royalty revenues | $477 · +9.4% |
| Total revenues | $16,583 · −0.4% |
| Cost of sales | $4,028 · −3.5% |
| Selling, informational and administrative expenses | $3,279 · +2.9% |
| Research and development expenses | $3,016 · +18.5% |
| Acquired in-process research and development expenses | $669 · −51.9% |
| Amortization of intangible assets | $1,128 · −7.8% |
| Restructuring charges and certain acquisition-related costs | $791 · +177% |
| Other (income)/deductions––net (incl. net interest expense) | $288 · −44.3% |
| Income from continuing operations before provision/(benefit) for taxes on income | $3,385 · +1.5% · 20.4% margin |
| Provision/(benefit) for taxes on income | $134 · vs −$216 · 4.0% effective rate |
| Net income attributable to noncontrolling interests | $10 · +11.1% |
| Net income attributable to Pfizer Inc. common shareholders | $3,242 · −8.4% · $0.56/sh · 19.6% margin |
Verdict: Pfizer's third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier (-0.4%), while GAAP net income fell 8% to $3,242 million and diluted EPS declined to $0.56 from $0.62. Pre-tax income from continuing operations edged up to $3,385 million from $3,334 million, but a tax charge of $134 million replaced a $216 million benefit.
Pfizer raised full-year 2026 revenue guidance to $62.0–64.0 billion from $60.5–62.5 billion and Adjusted diluted EPS guidance to $2.95–3.05 from $2.80–3.00. For the first nine months, revenues rose 2% to $46,067 million while net income fell 40% to $5,681 million. The company paid $7.3 billion of dividends, or $1.29 per share, in the first nine months, completed no share repurchases in 2026 and has $3.3 billion of remaining authorization.
Source and notation
Source: Pfizer earnings release, 8-K EX-99 of 11/03/2026 (SEC EDGAR).
Open as an image: Pfizer (PFE), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Pfizer (PFE) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/pfe. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/pfe"><img src="https://whoreportstoday.com/t/pfe/img/pfizer-pfe-earnings-sankey.png" alt="Pfizer (PFE) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/pfe">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/pfe/img/pfizer-pfe-earnings-sankey.png
<a href="https://whoreportstoday.com/t/pfe">Pfizer (PFE) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Paxlovid revenues fell $771 million (63%) and Comirnaty fell $339 million (29%) operationally, while Eliquis rose $513 million (25%) and Padcev rose $255 million (55%).
- Acquired in-process R&D expenses dropped to $669 million from $1,390 million.
- Restructuring and acquisition-related costs jumped to $791 million from $286 million, including $742 million of cost-reduction charges versus $236 million.
- R&D expenses rose 18% to $3,016 million from $2,546 million.
- Other deductions net fell to $288 million from $517 million: the prior-year quarter included a $260 million impairment and $191 million of legal charges, while this quarter had a $132 million gain on asset disposals and a $159 million contingent consideration charge.
- The effective tax rate was 3.9% versus (6.5)% a year earlier, when deferred tax liabilities were remeasured.
- Cost of sales fell to 24.3% of revenues from 25.0%, and diluted shares rose to 5,751 million from 5,714 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Albert BourlaChairman and Chief Executive Officer [1]
- Cecile GueganChief Financial Officer, Executive Vice President [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Pfizersince 2018
- Directorsince 2018
- Chairman and Chief Executive Officernow
Source: SEC EDGAR: DEF 14A proxy statement, 2026-03-12 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-03 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-03 · SEC EDGAR · 11/18/2026
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. · Text: Wikipedia, CC BY-SA 4.0, abridged
Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Market share (US pharma & biotech): ≈9% by TTM revenue.
Heads-up
- net income fell 8% y/y in Q3 2026
Net income for Q3 2026: $3,242M, −8% y/y. In the report's figures: revenue −0% y/y; costs grew faster than revenue: restructuring charges and certain acquisition-related costs +177% y/y, research and development expenses +19% y/y, net income attributable to noncontrolling interests +11% y/y. Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $62–64B (raised)EPS (non-GAAP) $2.95–3.05 | revenue $62.6BEPS (GAAP) $1.36 | revenue −1…+2% |
Same quarter a year ago (ended December 31, 2025): revenue $17.56B, EPS (GAAP) −$0.29
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +1%).
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Nov 3, 2026); every figure is checked against the release text.
PFE earnings history: past report dates
| Nov 3, 2026 Tue | 8:07 ambefore market open | Sep 27, 2026 | $16.6B−0% y/y | $0.56−10% y/y |
| Aug 4, 2026 Tue | 7:02 ambefore market open | Jun 28, 2026 | $15.0B+3% y/y | −$0.04 |
| May 5, 2026 Tue | 7:01 ambefore market open | Mar 29, 2026 | $14.5B+5% y/y | $0.47−10% y/y |
| Feb 3, 2026 Tue | 7:01 ambefore market open | Dec 31, 2025 | ≈$17.6B−1% y/y | ≈−$0.29 |
| Nov 4, 2025 Tue | 7:00 ambefore market open | Sep 28, 2025 | $16.7B−6% y/y | $0.62−21% y/y |
| Aug 5, 2025 Tue | 7:08 ambefore market open | Jun 29, 2025 | $14.7B+10% y/y | $0.51 |
| Apr 29, 2025 Tue | 8:02 ambefore market open | Mar 30, 2025 | $13.7B−8% y/y | $0.52−5% y/y |
| Feb 4, 2025 Tue | 8:11 ambefore market open | Dec 31, 2024 | ≈$17.8B+31% y/y | ≈$0.07 |
| Oct 29, 2024 Tue | 8:06 ambefore market open | Sep 29, 2024 | $17.7B+31% y/y | $0.78 |
| Jul 30, 2024 Tue | 8:04 ambefore market open | Jun 30, 2024 | $13.3B+2% y/y | $0.01−98% y/y |
| May 1, 2024 Wed | 8:11 ambefore market open | Mar 31, 2024 | $14.9B−20% y/y | $0.55−43% y/y |
| Jan 30, 2024 Tue | 8:04 ambefore market open | Dec 31, 2023 | ≈$13.5B−46% y/y | ≈−$0.59 |
| Oct 13, 2023 Fri | 5:30 pmafter market close | Oct 1, 2023 | $13.5B−40% y/y | −$0.42 |
| Aug 1, 2023 Tue | 8:09 ambefore market open | Jul 2, 2023 | $13.0B−53% y/y | $0.41−76% y/y |
Show all 14 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Pfizer: 15-year financials
| 2025 | 62,579 | 7,771 | 9,075 |
| 2024 | 63,627 | 8,031 | 9,835 |
| 2023 | 59,553 | 2,119 | 4,793 |
| 2022 | 101,175 | 31,372 | 26,031 |
| 2021 | 81,288 | 21,979 | 29,869 |
| 2020 | 41,651 | 9,159 | 12,177 |
| 2019 | 40,905 | 16,026 | 10,542 |
| 2018 | 40,825 | 11,153 | 13,843 |
| 2017 | 52,546 | 21,308 | 14,846 |
| 2016 | 52,824 | 7,215 | 14,369 |
| 2015 | 48,851 | 6,960 | 13,291 |
| 2014 | 49,605 | 9,135 | 15,885 |
| 2013 | 51,584 | 22,003 | 16,478 |
| 2012 | 54,657 | 14,570 | 15,419 |
| 2011 | 61,035 | 10,009 | 18,580 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Pfizer: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 208,160 | 86,476 | 64,638 | 1,142 | 42,898 | 36,984 |
| 2024 | 213,396 | 88,203 | 63,605 | 1,043 | 50,358 | 42,995 |
| 2023 | 226,501 | 89,014 | 71,757 | 2,853 | 43,333 | 47,794 |
| 2022 | 197,205 | 95,661 | 35,444 | 416 | 51,259 | 42,138 |
| 2021 | 181,476 | 77,201 | 37,831 | 1,944 | 59,693 | 42,671 |
| 2020 | 154,229 | 63,238 | 4,556 | 1,786 | 35,067 | 25,920 |
| 2019 | 167,594 | 63,143 | 51,332 | 1,121 | 32,803 | 37,304 |
| 2018 | 159,422 | 63,407 | 40,785 | 1,139 | 49,926 | 31,858 |
| 2017 | 171,797 | 71,308 | 43,184 | 1,342 | 41,141 | 30,427 |
| 2016 | 171,615 | 59,544 | 37,198 | 2,595 | 38,949 | 31,115 |
| 2015 | 167,381 | 64,720 | 28,818 | 3,641 | 43,804 | 29,399 |
| 2014 | 167,566 | 71,301 | 31,541 | 3,343 | 55,595 | 21,587 |
| 2013 | 172,101 | 76,307 | 35,522 | 2,183 | 56,244 | 23,366 |
| 2012 | 185,798 | 81,260 | 36,185 | 10,081 | 64,831 | 29,186 |
| 2011 | 188,002 | 82,190 | 34,932 | 3,182 | 60,817 | 28,909 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow, 2 years
| Year | CFO · Operating cash flow | CAPEX · Capital expenditure | FCF · Free cash flowcalculated | FCF margin, %calculated | Dividends paid | FCF / net income, %calculated | CFI · Investing cash flow | CFF · Financing cash flow |
|---|---|---|---|---|---|---|---|---|
| 20192019-12-31 | — | — | — | — | — | — | — | −8,485 |
| 20182018-12-31 | — | — | — | — | — | — | — | −20,441 |
More detailsHide details
$ millions, per fiscal year; ratios in %. “—” — no verified data or calculation not applicable.
How we calculate
CFO, CFI and CFF are net operating, investing and financing cash flows. CAPEX is a positive cash outflow for capital expenditure; its scope follows the issuer document line. FCF = CFO − CAPEX; lease repayments are not deducted separately. If no separately sourced numeric CAPEX amount is available, CAPEX and FCF calculations are omitted. FCF margin = FCF / same-year revenue × 100. FCF / net income = FCF / same-year income attributable to shareholders × 100; losses or zero income produce a dash. Revenue and income use this card’s indicators table; missing or mismatched periods produce no ratio. Dividends and common share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows; payments to noncontrolling interests and share-compensation withholding taxes are excluded. Zero requires document evidence. Buybacks appear only if at least one reviewed payment exists in the fifteen-year window. The window is fifteen years; years without a single value are omitted. All listed years stay open; CFI, CFF and buybacks for Russia and Kazakhstan appear under More details.
Snapshot reviewed: . Updated after annual filings and three checks against issuer documents. Unreviewed and interim periods are excluded from the annual series.
More: latest reported period
9 months ended 2026-09-27 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 8,825 | 6,356 | +2,469 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 4,812 | 4,905 | |
| · incl. stock-based comp (non-cash)share-based compensation | 883 | 574 | |
| Capexpurchases of property & equipment | −1,542 | −1,784 | +242 |
| Free cash flow ≈operating cash flow − capex | 7,283 | 4,572 | +2,711 |
| Investing activities, netcapex, acquisitions, securities | 865 | 4,795 | −3,930 |
| Financing activities, netdebt, buybacks, dividends | −9,025 | −10,900 | +1,875 |
| · incl. dividends paid | −7,347 | −7,326 | −21 |
| FX effect on cash | 16 | 36 | −20 |
| Net change in cash | 681 | 287 | +394 |
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 27, 2026: $89.0B (44% of total assets). Compare with other S&P 500 companies →
Corporate governance
1.5/2mostly good
- Jul 2016Pfizer agreed to pay $486M to settle a shareholder class action over concealed Celebrex and Bextra risks (court-approved in December 2016); in 2014 it paid $400M in another shareholder suit in New York. sec.gov ↗
- Feb 202610-K 2025: all common stock is of one class; the legal cases include no shareholder disclosure suits. sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Dec 2025Dividend per share rose from $1.53 (2020) to $1.72 (2025); diluted shares +1.4% over 5 years (XBRL). data.sec.gov ↗
Scoring: 2.0 −0.5 (criterion 9: $486M shareholder settlement over Celebrex/Bextra, approved by the court in Dec 2016) −0.25 (criterion 9: $400M shareholder settlement, 2014 — older than 10 years, half weight) = 1.25 → 1.5
- Share classes
- Single class of common stock ("all of one class", 10-K 2025 cover).
- Dilution
- Diluted shares 2020→2025 +1.4%; SBC 1.3% of revenue.
- Disclosure
- Full reporting, filed on time.
- Dividends
- Dividend raised every year: $1.53 (2020) → $1.72 (2025).
- Lawsuits & regulators
- Two shareholder settlements above $50M: $486M (court approval Dec 2016) — full deduction, $400M (2014) — older than 10 years, half weight. No shareholder suits or SEC disclosure cases in the current 10-K.
- Related parties
- No material related-party transactions disclosed.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Pfizer (PFE) earnings: FAQ
How does Pfizer make money?
Pfizer brought in $16.6 billion of revenue in Q3 2026, down 0.4% year over year. The largest source was Product revenues: $13.3 billion, or 80% of the total, followed by Alliance revenues ($2.85B, 17%) and Royalty revenues ($477M, 3%). Net income for the quarter was $3.24 billion, down 8.4% year over year.
When is PFE's next earnings date?
We have not yet seen an announcement of the date from Pfizer (PFE). Based on last year's report on Feb 3, 2026, the next report is expected around Feb 2, 2027.
What time does PFE report earnings?
Pfizer usually reports before market open: its latest results release was filed with the SEC at 8:07 am ET on Nov 3, 2026.
When did PFE last report earnings?
Pfizer reported Q3 2026 results on Nov 3, 2026.
What has Pfizer guided for FY2026?
Company guidance for FY2026: revenue $62–64B (raised); EPS (non-GAAP) $2.95–3.05. A year ago (FY2025): revenue $62.6B, EPS (GAAP) $1.36. Implied growth: revenue −1…+2%. Source: the company's earnings release (Form 8-K filed Nov 3, 2026).
Where can I find Pfizer's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to PFE's filings; this page breaks the latest report down in a Sankey chart.
What was PFE's net income in Q3 2026?
Pfizer reported net income of $3,242M for Q3 2026 (−8.4% year over year), under US GAAP.
How has Pfizer's revenue changed since 2011?
Per its 10-K filings, revenue was roughly flat: $61,035M in 2011 and $62,579M in 2025. The peak was $101,175M in 2022. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · TECH · Q4 FY2026 · TMO · Q3 2026 · UHS · Q3 2026 · all reports